Scarica l'app Stockscreener
0.2502
8.31%
0.0192
Precedente Chiudi:
$0.231
Aprire:
$0.2504
Volume 24 ore:
6,189
Relative Volume:
34.03
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-13.24M
Rapporto P/E:
-0.0283
EPS:
-8.83
Flusso di cassa netto:
$-16.85M
1 W Prestazione:
+8.31%
1M Prestazione:
-94.94%
6M Prestazione:
-97.91%
1 anno Prestazione:
-99.74%
Intervallo 1D:
$0.24
$0.2675
Intervallo di 1 settimana:
$0.24
$0.2675
Portata 52W:
$0.212
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Nome
Virpax Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta VRPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2504 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
ONC
Beone Medicines Ltd Adr
|
258.49 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.98 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.30 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.87 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com India
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Promising Nanotechnology Stocks To Watch NowMarch 22nd - MarketBeat
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals stock hits 52-week low at $0.18 - Investing.com
Nanotechnology Stocks To Follow Now – March 7th - Defense World
Virpax Looking To Use Met To Develop Intranasal Covid Vaccine -March 07, 2025 at 08:36 am EST - Marketscreener.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - The Bakersfield Californian
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - StockTitan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - StockTitan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Stock Market Update – Virpax Pharmaceuticals Stock Price Prediction 2025 - ldccbank
Virpax Pharmaceuticals Inc Azioni (VRPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.19%
Capitalizzazione:
|
Volume (24 ore):